Abstract
11 of 24 immunocompromised patients with mucocutaneous herpes simplex virus (HSV) infections were given intravenous acyclovir in a randomised double-blind placebo-controlled study. Patients receiving acyclovir experienced no major adverse effects. The median times to cessation of new lesion formation, lesion crusting, lesion healing, cessation of pain, and termination of viral shedding were shorter in the acyclovir-treated group than in the placebo group. The time-to-event probability curves for the acyclovir and placebo groups were significantly different for cessation of pain (p = 0.032) and termination of viral shedding (p = 0.004). The median times to termination of viral shedding were also statistically different (p = 0.045). Acyclovir seems to be a non-toxic and effective treatment for mucocutaneous HSV infections in immunocompromised patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1389-1392 |
| Number of pages | 4 |
| Journal | The Lancet |
| Volume | 317 |
| Issue number | 8235 |
| DOIs | |
| State | Published - Jun 27 1981 |
Bibliographical note
Funding Information:in part by grants AM 13083 and AM 18883 from the National Institutes of Health, and by a grant from Burroughs Wellcome Company, U.S.A.